Miscellaneous
Frequency of hypercholesterolemia after cardiac transplantation

https://doi.org/10.1016/0002-9149(88)90272-XGet rights and content

Abstract

Cardiac transplant patients are prone to accelerated coronary atherosclerosis. The mechanism by which this process occurs is not yet known, although immunologically mediated arterial injury is thought to play a primary role in its pathogenesis. Despite immunosuppressive potency, patients treated with cyclosporin A remain at significant risk for the development of accelerated atherosclerosis. It is hypothesized that cyclosporin A's hepatotoxic effects might contribute to the atherosclerotic process by impairing low density lipoprotein hepatic clearance in transplant patients, which would be reflected in a more atherogenic lipoprotein profile. To test this hypothesis, serum cholesterol levels were analyzed after transplantation. Significant and progressive increases in total cholesterol and in the total-to-high density lipoprotein cholesterol ratio were found. This atherogenic lipoprotein profile may contribute to accelerated atherosclerosis in cardiac transplant patients treated with cyclosporin A.

References (29)

  • WJ Hardin et al.

    Experimental induction of atheroarteriosclerosis by the synergy of allergic injury to arteries and lipid-rich diet

    Am J Pathol

    (1973)
  • DR Alonso et al.

    Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia

    Am J Pathol

    (1977)
  • ML Hess et al.

    Accelerated atherosclerosis in cardiac transplantation: role of cytotoxic B-cell antibodies and hyperlipidemia

    Circulation

    (1983)
  • C Zoja et al.

    Cyclosporininduced endothelial cell injury

    Lab Invest

    (1986)
  • Cited by (91)

    • Special Patient Populations: Transplant Recipients

      2023, Clinical Lipidology: A Companion to Braunwald's Heart Disease
    • Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?

      2016, Transplantation Reviews
      Citation Excerpt :

      Hyperlipidemia, as early as 6 months following transplantation, has been shown to be a strong risk factor for CAV [37,38]. When transplanted vasculature of animals were exposed to the same level of hyperlipidemia as native vessels, there was a significant increase in intimal thickness, greater angiogenesis and higher accumulation of T-lymphocytes within the allograft [39,40]. These findings suggest that additional benefits of statins may be through immunomodulatory and anti-inflammatory mechanisms in combination with lipid lowering effects.

    • Special Patient Populations: Transplant Recipients

      2009, Clinical Lipidology: A Companion to Braunwald's Heart Disease
    • Special Patient Populations: Transplant Recipients

      2008, Clinical Lipidology: A Companion to Braunwald's Heart Disease Expert Consult: Online and Print
    View all citing articles on Scopus
    View full text